BriaCell says Bria-MEL+ melanoma vaccine candidate hits genetic engineering milestone

• BriaCell reported a genetic engineering milestone for Bria-MEL+, advancing its personalized whole-cell melanoma vaccine program toward clinical development.
• Bria-MEL+ uses premanufactured cell lines selected via a saliva-based HLA match, aiming to avoid patient-by-patient manufacturing.
• Development work has started to support production for potential clinical use, positioning Bria-MEL+ as an expansion beyond breast cancer programs.
• The pipeline centers on Bria-IMT in a pivotal Phase 3 metastatic breast cancer trial; Bria-PROS+ received FDA clearance to begin testing.
• Melanoma incidence is projected at about 112,000 U.S. cases in 2026, with 8,510 expected deaths, underscoring the target market.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Briacell Therapeutics Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608240730PRIMZONEFULLFEED9814741) on August 24, 2026, and is solely responsible for the information contained therein.